Similar articles

• Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.

  Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. Ferlazzo G, et al. Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13. Lancet Infect Dis. 2018. PMID: 29452942
• Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.

  Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Hwang H, et al. Clin Infect Dis. 2021 Oct 20;73(8):1362-1369. doi: 10.1093/cid/ciab304. Clin Infect Dis. 2021. PMID: 33837767
• Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.

  Li Y, Sun F, Zhang W. Li Y, et al. Drug Dev Res. 2019 Feb;80(1):98-105. doi: 10.1002/ddr.21498. Epub 2018 Dec 11. Drug Dev Res. 2019. PMID: 30548290 Free PMC article. Review.
• Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.

  Yang JS, Kim KJ, Choi H, Lee SH. Yang JS, et al. Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563. Ann Lab Med. 2018. PMID: 30027700 Free PMC article.
• Bedaquiline and delamanid in tuberculosis.

  Esposito S, Bianchini S, Blasi F. Esposito S, et al. Expert Opin Pharmacother. 2015;16(15):2319-30. doi: 10.1517/14656566.2015.1080240. Epub 2015 Aug 19. Expert Opin Pharmacother. 2015. PMID: 26293803 Review.